Will metastasis occur while taking trametinib?

Trametinib is a targeted drug mainly used to treat tumors such as melanoma carrying BRAF V600E or V600K mutations. It inhibits the activity of MEK enzyme and blocks the proliferation signals of tumor cells, thereby achieving the purpose of controlling tumor growth. However, even if patients are taking trametinib, tumor metastasis or disease progression may still occur.

There are many reasons for metastasis, including the heterogeneity of the tumor itself. That is to say, even if some tumor cells are sensitive to trametinib and are inhibited, there may be some drug-resistant cells that have not been completely eliminated. These cells have the opportunity to develop into new lesions and cause metastasis. In addition, after long-term use of trametinib, tumor cells in some patients may develop new genetic mutations, resulting in drug resistance, which is also one of the important mechanisms of metastasis or recurrence.

Trametinib is often used in combination with dabrafenib. The combination of the two has been proven to be better than monotherapy in prolonging progression-free survival and overall survival. However, even so, it cannot completely eliminate the risk of tumor metastasis. Therefore, during the period of taking it, regular imaging examinations, such as CT or MRI, are still needed to monitor changes in lesions and detect possible metastasis in a timely manner.
In short, patients taking trametinib cannot completely rule out the possibility of metastasis, especially if the treatment course is long or drug resistance occurs. Patients should actively cooperate with doctors for follow-up visits and promptly report any symptoms of discomfort. If necessary, the treatment plan should be adjusted or combined with other drugs for intervention, so as to improve the overall treatment effect and delay the progression of the disease.
Reference: https://go.drugbank.com/drugs/DB08911